Many methods to measure pharmacodynamic endpoints are currently available, for instance, enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Measuring these endpoints is a crucial step in optimizing your compound to transition into clinical trials. However, when it comes to sensitivity, accuracy, and economic efficiency, Meso Scale Discovery (MSD) biomarker assays prove to be an advantageous option to further develop your compound. The platform comprises of different assay kits that allow rapid measurement of the levels of a specific biomarker within a single, small-volume sample.
How it works:
The MSD technology leverages electrochemiluminescence technology through parallel processing of biological assays and provides a quantitative measure of the analyte with your sample. There are over 500 assay panels, custom panels, and reagent kits enabling for a large variety of protein analyses. You can view the whole list of available MSD assays here
If your analyte is not already validated within one of the available kits, InnoSer can provide you with the expertise coupled with validation services enabling you to assess your specific analyte. By introducing biomarker discovery early on in your research through this customizable approach you will increase the translational power of your preclinical research.
Benefits:
With MSD’s novel technology, we now have the capabilities to provide greater sensitivity, precision, reproducibility, and absolute quantification. These added benefits come with faster turnaround times for your results and lower costs than traditional methods like ELISA or Western Blot due to its multiplex system that allows an analysis of up to 10 markers in a single well.
With a wide range of applications, this analysis technique can be applied to many different study types adding value and saving time to a range of projects. The ready to use validated panels include:
- Cytokines & Chemokines
- Oncology
- Angiogenesis & Vascular analytes
- Bone Metabolism
- Cardiovascular
- Metabolism
- Inflammation
- Intracellular Signaling
- Neurodegeneration
- Toxicology
- GPCR-ligand binding proteins
- Immunology
- Growth factors
- Hypoxia
Through thorough preclinical investigation, we can increase the translatability of your lead compounds from the preclinical stage into clinical trials. Using a variety of techniques combined with the most appropriate readouts, InnoSer will work closely with you in providing expertise at every step of your drug development process.
Do you have more questions about how MSD technology could benefit your research?
Want to read more?
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
Top 4 Multi-Organ-on-a-Chip TissUse Assays and Why You Should Include them in Your Preclinical Research in 2025
Preclinical research is evolving rapidly, and staying ahead means embracing innovative tools that streamline processes and provide actionable insights. Multi-Organ-on Chip (MOC) assays, also known as microphysiological systems (MPS), are among the most exciting...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...